This provider's $31.7M in total Medicare payments ranks in the 97th percentile of Clinical Laboratory providers nationally.
Medicare payments to this provider grew 75927% from 2018 to 2023.
AI-generated analysis based on Medicare payment data.
Notable: Payments increased 36363% in 2019
Year-over-year payment surges can indicate changes in practice volume, new services, or billing pattern shifts.
Average per-service amounts submitted by the provider compared to what Medicare actually paid — the gap represents the markup.
| Year | Avg Submitted | Avg Paid | Markup Ratio | Gap per Service | Total Payments | Services | Beneficiaries |
|---|---|---|---|---|---|---|---|
| 2018 | $753.73 | $147.71 | 5.10x | $606.02 | $5.5K | 37 | 2 |
| 2019 | $1.4K | $664.92 | 2.08x | $716.13 | $2.0M | 3.0K | 9 |
| 2020 | $827.94 | $400.79 | 2.07x | $427.15 | $2.2M | 5.6K | 8 |
| 2021 | $803.37 | $370.95 | 2.17x | $432.42 | $20.5M | 55.2K | 21 |
| 2022 | $558.20 | $331.62 | 1.68x | $226.58 | $2.8M | 8.4K | 22 |
| 2023 | $406.16 | $390.03 | 1.04x | $16.13 | $4.2M | 10.7K | 22 |
| Code | Description | Services | Payments | Avg/Service | Markup |
|---|---|---|---|---|---|
| 81408 | Molecular pathology procedure level 9 | 7.4K | $14.8M | $2.0K | 2.01x |
| 81406 | Molecular pathology procedure level 7 | 3.8K | $1.1M | $282.43 | 2.28x |
| 81401 | Molecular pathology procedure level 2 | 7.7K | $1.1M | $136.66 | 2.01x |
| 81226 | Gene analysis (cytochrome p450, family 2, subfamily d, polypeptide 6) common variants | 2.1K | $947.1K | $447.82 | 1.83x |
| 81307 | Gene analysis (partner and localizer of brca2) full sequence analysis | 1.3K | $874.8K | $663.20 | 1.04x |
| 81238 | Gene analysis (coagulation factor ix) full sequence analysis | 1.4K | $859.0K | $592.80 | 2.24x |
| 81350 | Gene analysis (udp glucuronosyltransferase 1 family, polypeptide a1) for detection of common variants | 3.6K | $836.2K | $233.13 | 2.01x |
| 81317 | Gene analysis (postmeiotic segregation increased 2 [s cerevisiae]) full sequence analysis | 1.3K | $832.2K | $663.12 | 1.04x |
| 81404 | Molecular pathology procedure level 5 | 3.0K | $831.4K | $274.83 | 3.99x |
| 81298 | Gene analysis (muts homolog 6 [e coli]) full sequence analysis | 1.3K | $794.6K | $629.16 | 1.04x |
| 81232 | Gene analysis (dihydropyrimidine dehydrogenase) for common variant | 3.6K | $619.8K | $174.15 | 2.01x |
| 81249 | Gene analysis (glucose-6-phosphate dehydrogenase) full sequence analysis | 896 | $526.8K | $588.00 | 1.04x |
| 81328 | Gene analysis (solute carrier organic anion transporter family, member 1b1) for common variant | 3.0K | $520.7K | $174.66 | 1.96x |
| 81227 | Gene analysis (cytochrome p450, family 2, subfamily c, polypeptide 9) common variants | 3.0K | $517.8K | $174.69 | 1.97x |
| 81335 | Gene analysis (thiopurine s-methyltransferase) for common variant | 2.8K | $498.0K | $174.81 | 2.00x |
| 81230 | Gene analysis (cytochrome p450 family 3 subfamily a member 4) for common variant | 2.8K | $497.9K | $174.81 | 2.00x |
| 81231 | Gene analysis (cytochrome p450 family 3 subfamily a member 5) for common variant | 2.8K | $497.7K | $174.81 | 2.00x |
| 81162 | Gene analysis (breast cancer 1 and 2) of full sequence and analysis for duplication or deletion variants | 266 | $476.2K | $1.8K | 1.03x |
| 81225 | Gene analysis (cytochrome p450, family 2, subfamily c, polypeptide 19) common variants | 1.6K | $476.0K | $290.23 | 1.88x |
| 81223 | Gene analysis (cystic fibrosis transmembrane conductance regular) full gene sequence | 905 | $442.6K | $489.03 | 1.04x |
This provider submits charges 1.96 times higher than what Medicare actually pays.
A markup ratio of 1.96x means for every $100 Medicare pays, this provider initially charges $196. This is lower than the national average.
Always verify provider credentials and location before scheduling appointments. This data reflects Medicare payments and may not include all practice locations.
Other Clinical Laboratory providers in NJ for peer comparison.
| Provider | Location | Total Payments | Status |
|---|---|---|---|
| Laboratory Corporation Of America Holdings | Raritan, NJ | $1.2B | ⚠️ Flagged |
| Quest Diagnostics Incorporated | Clifton, NJ | $927.2M | ⚠️ Flagged |
| Bioreference Health, Llc | Elmwood Park, NJ | $841.0M | ⚠️ Flagged |
| Accu Reference Medical Lab, Llc | Linden, NJ | $204.9M | ⚠️ Flagged |
| Aculabs Inc | East Brunswick, NJ | $91.5M | ✓ Clear |
Share this provider's Medicare payment information
Last Updated: February 2026 (data through 2023, the latest CMS release)
Note: All data is from publicly available Medicare records. OpenMedicare is an independent journalism project not affiliated with CMS.
Believe this data is inaccurate? Dispute this data